According to The Insight Partners' research, the Asia Pacific health economics and outcome research (HEOR) services market was valued at US$ 228.23 million in 2024 and is expected to reach US$ 540.54 million by 2031, registering a CAGR of 14.8% from 2024 to 2031. Emergence of precision medicines and growing healthcare spending are among the critical factors attributed to the Asia Pacific health economics and outcome research (HEOR) services market expansion.
Precision medicine is an emerging segment in the healthcare industry. Research and development have shown promising results in the betterment of people and health improvement. However, despite various developments and improvements, there is a lack of evidence, thresholds, and reimbursement scenarios. Various researchers, payers, healthcare service providers, and market players are working to deploy new insights into personalized or precision medicine applications in early drug development and their consequences for health technology assessment. These provide ample growth opportunities for HEOR service providers to enhance their services for strategy and consulting, real-world evidence, modeling and microsimulation, and evidence synthesis associated with precision medicine. In addition, the HEOR guidelines and frameworks can clarify the outcomes and their impacts caused by regulatory and reimbursement policies for precision medicine applications. Moreover, they are expected to guide research investments to improve the appropriate use of precision medicine. Thus, the emergence of precision medicine is expected to provide vital growth opportunities for the market during the forecast period.
On the contrary, restrictions on access to real-world data (RWD) hamper the growth of Asia Pacific health economics and outcome research (HEOR) services market.
Based on service, the Asia Pacific health economics and outcome research (HEOR) services market is segmented into economic modelling or evaluation, real world data analysis and information system, market access solutions and reimbursement, clinical outcome, and others. The economic modelling or evaluation segment held 30.1% share of the Asia Pacific health economics and outcome research (HEOR) services market in 2024, amassing US$ 68.61 million. It is projected to garner US$ 167.33 million by 2031 to expand at 13.6% CAGR during 2024-2031.
By service provider, the Asia Pacific health economics and outcome research (HEOR) services market is bifurcated into contract research organizations and consultancy. The contract research organizations segment held 69.4% share of the Asia Pacific health economics and outcome research (HEOR) services market in 2024, amassing US$ 158.29 million. It is projected to garner US$ 381.68 million by 2031 to expand at 13.4% CAGR during 2024-2031.
By end user, the Asia Pacific health economics and outcome research (HEOR) services market is segmented into biotechnology and pharmaceutical companies, healthcare payers, government organizations, and healthcare providers. The biotechnology and pharmaceutical companies segment held 39.7% share of the Asia Pacific health economics and outcome research (HEOR) services market in 2024, amassing US$ 90.65 million. It is projected to garner US$ 222.70 million by 2031 to expand at 13.7% CAGR during 2024-2031.
By country, the Asia Pacific health economics and outcome research (HEOR) services market is categorized into China, Japan, India, South Korea, Australia, and the Rest of APAC. China held 27.5% share of Asia Pacific health economics and outcome research (HEOR) services market in 2024, amassing US$ 62.75 million. It is projected to garner US$ 152.82 million by 2031 to expand at 13.6% CAGR during 2024-2031.
Key players operating in the health economics and outcome research (HEOR) services market are PharmaLex GmbH; ICON Plc; IQVIA Holdings Inc; Syneos Health Inc; Optum Inc; Certara Inc.; ExlService Holdings, Inc.; Avalon Health Economics LLC; Axtria, Inc.; and McKesson Corp, among others.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com